Our lead product for severe pneumonia, rhu-pGSN, has application for COVID19.

Chief Executive Officer, Susan L. Levinson, PhD.

Susan Levinson is a co-founder and the CEO of BioAegis, with over 30 years of life sciences consulting and pharmaceutical experience spanning the entire value chain, from the lab bench to marketing.

Prior to BioAegis, Dr. Levinson was the President of The Strategic Choice, a management consulting firm she founded after a successful career in the pharmaceutical industry. Dr. Levinson held executive positions in Business Strategy and Marketing Planning for Novartis Pharmaceuticals, leading key initiatives, including the implementation of a global brand planning model and managing the US annual strategic and tactical planning process. Prior to this, Dr. Levinson was responsible for New Product Marketing for women’s health, osteoporosis and chronic wound markets for the U.S.

She began her career at Novartis as Director of Licensing for the former Ciba-Geigy organization, where she led licensing strategy and negotiations within the Bone, Inflammation, Pulmonary and Oncology therapeutic areas. She began her career in Research, where as a Principal Scientist, she managed drug discovery programs at Ortho Pharmaceutical.

Susan has a B.S in Biochemistry from University of Wisconsin and a Ph.D. in Biomedical Sciences from Mount Sinai School of Medicine.